Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231957 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL3020728 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL7132014 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL3018149 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL20214124 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL20214720 | 1.00 | ESR1 (0.55) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL7358263 | 0.91 | ESR1 (0.46) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL3412848 | 0.88 | NQO2 (0.44) | ESR1ESR2CYP19A1LMNASLC6A4 | |
| SCHEMBL20235166 | 0.87 | ESR1 (0.51) | ESR1ESR2PPARGPPARACYP19A1 | |
| SCHEMBL28750802 | 0.87 | ESR1 (0.51) | ESR1ESR2PPARGPPARACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| CN-102186825-A | Aryl gpr120 receptor agonists and uses thereof | METABOLEX INC | 2011-09-14 | — | — | CN | disclosed |
| EP-2350016-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| EP-1414809-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011842-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ESR1 488/4885ESR2 150/4885PPARG 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.